Literature DB >> 18821042

Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci.

Haruki Koike1, Yuichi Kawagashira, Masahiro Iijima, Masahiko Yamamoto, Naoki Hattori, Fumiaki Tanaka, Masaaki Hirayama, Yukio Ando, Shu-ichi Ikeda, Gen Sobue.   

Abstract

BACKGROUND: Through the development of gene diagnostic techniques, late-onset transthyretin Met30-associated familial amyloid polyneuropathy (FAP TTR Met30) has been shown to be more prevalent than is generally believed.
OBJECTIVE: To examine the electrophysiological features of late-onset FAP TTR Met30 unrelated to endemic foci.
METHODS: Nerve conduction findings in 44 cases with an onset of more than 50 years of age in a non-endemic area were assessed and compared with findings from 21 earlier-onset cases related to endemic foci.
RESULTS: The extent of the reduction of the compound muscle action potential and, especially, the sensory nerve action potential was more profound in the late-onset group even when the decline of these indices with aging in normal control subjects was taken into account. The feature of predominant lower-limb involvement seemed to be more conspicuous in the late-onset group. Electrophysiological indices tended to be aggravated as the duration of neuropathic symptoms increased in the early-onset group, while most of these indices in the lateonset group did not show this correlation. A slowing of conduction velocity and a prolongation of distal latency, which suggests demyelination, were conspicuous in some patients. Pathologically, a predominant loss of small-fibers was not conspicuous in sural nerve biopsy specimens from late-onset patients. Large myelinated fiber density showed a negative correlation with the disease duration in early-onset cases, but not in late-onset cases.
CONCLUSIONS: Electrophysiological differences between late- and early-onset cases were present, probably reflecting the different underlying pathogenic mechanisms of neuropathy. The demyelinating feature does not exclude the possibility of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18821042     DOI: 10.1007/s00415-008-0962-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  37 in total

1.  Anticipation in early- but not late-onset familial amyloid polyneuropathy (TTR met 30) in Japan.

Authors:  K Misu; N Hattori; Y Ando; S Ikeda; G Sobue
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

2.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

Review 3.  Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients.

Authors:  Naoki Hattori; Masahiko Yamamoto; Tsuyoshi Yoshihara; Haruki Koike; Masanori Nakagawa; Hiroo Yoshikawa; Akio Ohnishi; Kiyoshi Hayasaka; Osamu Onodera; Masayuki Baba; Hitoshi Yasuda; Toyokazu Saito; Kenji Nakashima; Jun-ichi Kira; Ryuji Kaji; Nobuyuki Oka; Gen Sobue
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

4.  Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features.

Authors:  K i Misu; N Hattori; M Nagamatsu; S i Ikeda; Y Ando; M Nakazato; Y i Takei; N Hanyu; Y Usui; F Tanaka; T Harada; A Inukai; Y Hashizume; G Sobue
Journal:  Brain       Date:  1999-10       Impact factor: 13.501

5.  Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form.

Authors:  Haruki Koike; Ken-ichiro Misu; Shu-ichi Ikeda; Yukio Ando; Masamitsu Nakazato; Eiko Ando; Masahiko Yamamoto; Naoki Hattori; Gen Sobue
Journal:  Arch Neurol       Date:  2002-11

6.  Postgastrectomy polyneuropathy with thiamine deficiency is identical to beriberi neuropathy.

Authors:  Haruki Koike; Masahiro Iijima; Keiko Mori; Naoki Hattori; Hiroki Ito; Masaaki Hirayama; Gen Sobue
Journal:  Nutrition       Date:  2004 Nov-Dec       Impact factor: 4.008

7.  Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy.

Authors:  Haruki Koike; Masahiro Iijima; Makoto Sugiura; Keiko Mori; Naoki Hattori; Hiroki Ito; Masaaki Hirayama; Gen Sobue
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis.

Authors:  Martin Berghoff; Madeera Kathpal; Faisal Khan; Martha Skinner; Rodney Falk; Roy Freeman
Journal:  Ann Neurol       Date:  2003-06       Impact factor: 10.422

9.  Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy.

Authors:  M M Reilly; D Adams; D R Booth; M B Davis; G Said; M Laubriat-Bianchin; M B Pepys; P K Thomas; A E Harding
Journal:  Brain       Date:  1995-08       Impact factor: 13.501

10.  Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate.

Authors:  G Holmgren; P M Costa; C Andersson; K Asplund; L Steen; L Beckman; P O Nylander; A Teixeira; M J Saraiva; P P Costa
Journal:  J Med Genet       Date:  1994-05       Impact factor: 6.318

View more
  10 in total

1.  The spectrum of clinicopathological features in pure autonomic neuropathy.

Authors:  Haruki Koike; Rina Hashimoto; Minoru Tomita; Yuichi Kawagashira; Masahiro Iijima; Shigeru Koyano; Takayuki Momoo; Hiroyuki Yuasa; Shigehisa Mitake; Mana Higashihara; Kenichi Kaida; Daisuke Yamamoto; Shin Hisahara; Shun Shimohama; Yoshiharu Nakae; Ken Johkura; Steven Vernino; Gen Sobue
Journal:  J Neurol       Date:  2012-02-24       Impact factor: 4.849

2.  Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Authors:  Maike F Dohrn; Christoph Röcken; Jan L De Bleecker; Jean-Jacques Martin; Matthias Vorgerd; Peter Y Van den Bergh; Andreas Ferbert; Katrin Hinderhofer; J Michael Schröder; Joachim Weis; Jörg B Schulz; Kristl G Claeys
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

Review 3.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

4.  Carpal tunnel syndrome and associated symptoms as first manifestation of hATTR amyloidosis.

Authors:  Chafic Karam; Diana Dimitrova; Megan Christ; Stephen B Heitner
Journal:  Neurol Clin Pract       Date:  2019-08

5.  Hereditary Transthyretin Amyloidosis in Eight Chinese Families.

Authors:  Ling-Chao Meng; He Lyu; Wei Zhang; Jing Liu; Zhao-Xia Wang; Yun Yuan
Journal:  Chin Med J (Engl)       Date:  2015-11-05       Impact factor: 2.628

6.  Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.

Authors:  Louise-Laure Mariani; Pierre Lozeron; Marie Théaudin; Zoia Mincheva; Aissatou Signate; Beatrice Ducot; Vincent Algalarrondo; Christian Denier; Clovis Adam; Guillaume Nicolas; Didier Samuel; Michel S Slama; Catherine Lacroix; Micheline Misrahi; David Adams
Journal:  Ann Neurol       Date:  2015-10-07       Impact factor: 10.422

Review 7.  Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.

Authors:  Yoshiki Sekijima; Mitsuharu Ueda; Haruki Koike; Sonoko Misawa; Tomonori Ishii; Yukio Ando
Journal:  Orphanet J Rare Dis       Date:  2018-01-17       Impact factor: 4.123

Review 8.  Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.

Authors:  Marco Luigetti; Angela Romano; Andrea Di Paolantonio; Giulia Bisogni; Mario Sabatelli
Journal:  Ther Clin Risk Manag       Date:  2020-02-21       Impact factor: 2.423

Review 9.  Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.

Authors:  Haruki Koike; Masahisa Katsuno
Journal:  Neurol Ther       Date:  2020-09-18

10.  Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Authors:  Márcia Waddington-Cruz; Yukio Ando; Leslie Amass; Jan Kiszko; Doug Chapman; Yoshiki Sekijima
Journal:  J Peripher Nerv Syst       Date:  2021-05-07       Impact factor: 3.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.